With low efficacy and high toxicity accounting for 70% of Phase II and 87% of Phase III clinical attrition, improving predictive in vitro models has never been such a high priority.
The 3rd Annual Developing More Predictive In Vitro Models Summit will showcase a range of new platforms and technologies that address this issue directly. High potential compounds will be prioritized, toxicity mitigated and clinical strategy directed by development and validation of this new breed of in vitro models.
During research for this meeting, your peers asked for an agenda packed full with the latest improvements in established in vitro models and exciting developments in 3D culture, stem cell and lab-on-a-chip technologies. With candid discussion on these issues guaranteed from senior level figures at the FDA, Novartis, Roche, Abbott, Pfizer and many more, this meeting will provide the most valuable strategic learning experience of the year.
Don’t miss out on this chance to go back to the lab with the tools to direct your preclinical and clinical strategy towards improved clinical performance.
“Excellent state-of-the-art for in vitro technology and practical pharma examples. An extremely good snapshot of where the field is.” Katya Tsaioun, CSO, Cyprotex
“Very good mix of speakers from various origins. Very valuable.” UCB Pharma
“An excellent opportunity to find out what other pharma are doing and what’s emerging. Very valuable.” AstraZeneca
“Good exchange. Interesting topics and a great mix of industry and academia. Collegial exchange of ideas are always valuable.” Genentech